Shukra Pharmaceuticals Ltd (SHUKRAPHAR) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Shukra Pharmaceuticals Ltd stock ₹9.14, price ₹79.97, that is 88.6% below the price, quality 54 out of 100. Rating: strongly overvalued. Calculated from audited financials with 16 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 2, 2026.
How to read this chart
60‑month range ₹0.2245 – ₹79.97 · fair‑value band ₹6.85 – ₹11.42 · the ₹79.97 price screens above the ₹9.14 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 2, 2026.
Follow Shukra Pharmaceuticals in your weekly email
Every Wednesday you see whether Shukra Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Shukra Pharmaceuticals Ltd (SHUKRAPHAR) currently trades at ₹79.97, while our model-based Fair Value estimate is ₹9.14, 89% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹23.16 per share, and 0 of the 16 models we run sit above the ₹79.97 price.
Bear case: the Asset-Based group reads lowest at ₹1.27, and 16 of the 16 models stay below the price. Data coverage for this calculation is low.
Scenario range: ₹6.85 (bear) to ₹11.42 (bull), the price of ₹79.97 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 54/100 (solid quality), in the Health Care sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Shukra Pharmaceuticals Ltd reported revenue of ₹567M in FY2026 versus ₹205M in FY2022, a compound +29.0%/yr. Reported net income was ₹221M in FY2026, compounding +132.8%/yr from FY2022. FY2022 was a trough year, so the rate overstates the trend.
Key figures
Market cap ₹35.0B (≈ $373M) Small · P/E ratio 97.5 · P/S ratio 46.8 · EPS (TTM) ₹0.8200 · Dividend yield 0.0% · Net margin 45.4% · Return on equity 28.9% · Return on assets (EBIT) 12.6% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 84 out of 100 (medium confidence).
What moves the price
The share trades at its 52-week high and 194% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Health Care peers we cover trades at −16% fair-value upside, at −89%, SHUKRAPHAR screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (₹0.1100 to ₹23.64). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear₹6.85Fair Value ₹9.14Bull₹11.42
Price ₹79.97 · Downside -88.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 7 months old). Earnings retained since then (₹0.4927 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+74.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+38.3%
Start year 2021 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+39.0%
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+51.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+51.8%
Dividend (yield on the price)0.0%
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.2% → 45%
⚠ Revenue per share shrinking 48.6%/yr over ~5Y (margins intact) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Compare Shukra Pharmaceuticals Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceuticals · 54 stocks
Beats the industry median on 7/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score54 · Above median
Fair Value upside−88.6% · Bottom 25%
Profitability
Return on equity (12 months)28.9% · Top 25%
Return on assets18.8% · Top 25%
Net margin (12 months)45.4% · Top 25%
Operating margin (12 months)79.1% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)336.3% · Top 25%
Dividend yield (12 months)0.0% · Bottom 25%
Balance sheet
Debt / equity0.04× · Below median
Valuation Multiplesvs Pharmaceuticals median · lower = cheaper
P/E (12 months)97.5× · Priciest 25%
P/B38.97× · Priciest 25%
P/S (12 months)46.78× · Priciest 25%
EV/EBITDA69.4× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 14
FUTURE (revenue growth)100· sector 51
PAST (return on equity)100· sector 15
HEALTH (low debt)98· sector 98
DIVIDEND (yield)0· sector 26
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Shukra Pharmaceuticals Ltd (SHUKRAPHAR) overvalued or undervalued?
As of Nov 2, 2026, our model estimates a fair value of ₹9.14 versus a price of ₹79.97, about 89% lower (overvalued).
What is the fair value of SHUKRAPHAR?
Our model-based fair value for Shukra Pharmaceuticals Ltd is ₹9.14 (as of Nov 2, 2026), built from audited fundamentals. The current price: ₹79.97.
What is the quality score of SHUKRAPHAR?
Shukra Pharmaceuticals Ltd has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Shukra Pharmaceuticals Ltd (SHUKRAPHAR)?
Our model-based price target is the fair value of ₹9.14 (as of Nov 2, 2026) from 16 valuation models. Cautious scenario ₹6.85, optimistic scenario ₹11.42. It is a calculation from audited fundamentals, not an analyst target.
What is the Shukra Pharmaceuticals Ltd stock forecast for 2026?
Our models put fair value at ₹9.14, about 89% lower versus a price of ₹79.97 (overvalued). Cautious scenario ₹6.85, optimistic scenario ₹11.42. The calculation is refreshed regularly with new filings.
What is the revenue of Shukra Pharmaceuticals Ltd (SHUKRAPHAR)?
Shukra Pharmaceuticals Ltd reported trailing-twelve-month revenue of about ₹749M (latest available figure, as of Nov 2, 2026).
Does Shukra Pharmaceuticals Ltd pay a dividend?
Shukra Pharmaceuticals Ltd currently shows a dividend yield of 0.01% relative to its recent price (as of Nov 2, 2026).
How much is the dividend of Shukra Pharmaceuticals Ltd (SHUKRAPHAR) and when is the ex-dividend date?
Shukra Pharmaceuticals Ltd pays a dividend of ₹0.01 per share a year, a dividend yield of 0.0%. The last ex-dividend date was Sep 21, 2026. A dividend has been paid every year since 2022. The payout ratio is 1.2% of earnings. Our assessment: Token dividend. At a yield of 0.0% the dividend is symbolic. On paper it is not fully covered by earnings or free cash flow, but at this size that hardly matters: even scrapping it entirely would cost less than 0.0% a year, and coverage ratios on amounts this small swing with ordinary working-capital movements. Judge this company on its business, not on its dividend.
What is the intrinsic value of Shukra Pharmaceuticals Ltd (SHUKRAPHAR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Shukra Pharmaceuticals Ltd it is ₹9.14 per share (as of Nov 2, 2026), against a price of ₹79.97. It is the blended result of 16 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Shukra Pharmaceuticals Ltd stock overvalued or undervalued in 2026?
As of Nov 2, 2026, SHUKRAPHAR trades above its calculated fair value: price ₹79.97, fair value ₹9.14, a gap of about −89% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SHUKRAPHAR?
No. The price is what the market pays today (₹79.97); the fair value is what the company's own numbers justify (₹9.14). For Shukra Pharmaceuticals Ltd the two are ₹70.83 per share apart. That gap is exactly why we show both numbers side by side.
How much is Shukra Pharmaceuticals Ltd worth?
The market values Shukra Pharmaceuticals Ltd at about ₹35.0B (market capitalisation, as of Nov 2, 2026). Per share that is ₹79.97; our models calculate a fair value of ₹9.14 per share.
What do the bullish and bearish scenarios say about SHUKRAPHAR?
Our models span a range for Shukra Pharmaceuticals Ltd: cautious scenario ₹6.85, base ₹9.14, optimistic ₹11.42 per share (as of Nov 2, 2026, price ₹79.97). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of SHUKRAPHAR?
Shukra Pharmaceuticals Ltd trades at a price-to-earnings ratio of 97.5 (as of Nov 2, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹9.14 is built from several models across several years. Other multiples: P/B 39.0, P/S 46.8, EV/EBITDA 69.4.
How solid is the balance sheet of Shukra Pharmaceuticals Ltd (SHUKRAPHAR)?
Balance-sheet figures for Shukra Pharmaceuticals Ltd (as of Nov 2, 2026): return on equity 28.9%, debt of 0.04 per unit of equity. They feed the Quality Score of 54/100, which measures business quality independently of the share price.
How far is SHUKRAPHAR from its 52-week high?
Shukra Pharmaceuticals Ltd trades at ₹79.97, at its 52-week high of ₹79.97 and 194% above the low of ₹27.23 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ₹9.14 is for.
Which stocks are comparable to Shukra Pharmaceuticals Ltd?
From the same area (Health Care) we also value ST Pharm Co, Caregen Co, Oscotec Inc, DongKook Pharmaceutical Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Shukra Pharmaceuticals Ltd stock attractive at the current price?
The data as of Nov 2, 2026: price ₹79.97, calculated fair value ₹9.14 (−89%), Quality Score 54/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SHUKRAPHAR calculated?
We run Shukra Pharmaceuticals Ltd through 16 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹9.14 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Shukra Pharmaceuticals Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Shukra Pharmaceuticals Ltd (SHUKRAPHAR)?
The closing price on Nov 6, 2026 was ₹79.97. Our model-based fair value is ₹9.14, about 89% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Shukra Pharmaceuticals Ltd right now?
The price sits above even our optimistic bull case (₹11.42). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (54/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Shukra Pharmaceuticals Ltd
How large is the market capitalisation of Shukra Pharmaceuticals Ltd (SHUKRAPHAR)?
The market capitalisation of Shukra Pharmaceuticals Ltd is ₹35.0B (≈ $373M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Shukra Pharmaceuticals Ltd (SHUKRAPHAR)?
The price-to-sales ratio of Shukra Pharmaceuticals Ltd is 46.8 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Shukra Pharmaceuticals Ltd (SHUKRAPHAR)?
Earnings per share at Shukra Pharmaceuticals Ltd are ₹0.8200 (price ÷ EPS = P/E 97.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Shukra Pharmaceuticals Ltd (SHUKRAPHAR)?
The dividend yield of Shukra Pharmaceuticals Ltd is 0.0% (payout 1.2%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Shukra Pharmaceuticals Ltd (SHUKRAPHAR)?
The net margin of Shukra Pharmaceuticals Ltd is 45.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Shukra Pharmaceuticals Ltd (SHUKRAPHAR)?
The return on equity (ROE) of Shukra Pharmaceuticals Ltd is 28.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Shukra Pharmaceuticals Ltd (SHUKRAPHAR)?
On an EBIT basis the return on assets of Shukra Pharmaceuticals Ltd is 12.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Shukra Pharmaceuticals Ltd (SHUKRAPHAR)?
The operating margin of Shukra Pharmaceuticals Ltd is 79.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Shukra Pharmaceuticals Ltd (SHUKRAPHAR)?
Revenue at Shukra Pharmaceuticals Ltd is growing +336% versus a year earlier (3y avg −1.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Shukra Pharmaceuticals Ltd (SHUKRAPHAR)?
Earnings per share at Shukra Pharmaceuticals Ltd are growing +14.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Shukra Pharmaceuticals Ltd (SHUKRAPHAR) generate?
The free cash flow of Shukra Pharmaceuticals Ltd is −₹118M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Shukra Pharmaceuticals Ltd (SHUKRAPHAR) carry?
The net debt of Shukra Pharmaceuticals Ltd is ₹41.8M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Shukra Pharmaceuticals Ltd in the live analysis
One click puts Shukra Pharmaceuticals Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 2, 2026